Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jan M. Prins"'
Autor:
Jan M. Prins, Legese A. Mekuria, Alemayehu Worku Yalew, Mirjam A. G. Sprangers, Pythia T. Nieuwkerk
Publikováno v:
Antiviral therapy, 21(5), 385-396. International Medical Press Ltd
Background Plasma viral load (pVL) is a key indicator of therapeutic response in HIV-infected patients receiving combination antiretroviral therapy (cART), but is often unavailable in routine clinical care in resource-limited settings. Previous model
Autor:
Suzanne Jurriaans, Joep M. A. Lange, Colette Smit, Frank P. Kroon, Ard van Sighem, Jan M. Prins, Frank de Wolf, Shuangjie Zhang, Luuk Gras, Peter Reiss
Publikováno v:
Antiviral therapy, 15(4), 555-562. International Medical Press Ltd
Antiviral Therapy, 15(4), 555-562
Antiviral Therapy, 15(4), 555-562
Background Transient episodes of HIV type-1 viraemia are frequently observed in patients on suppressive combination antiretroviral therapy (cART). We studied the effect of such episodes and of treatment interruptions on clinical outcome and immunolog
Autor:
Sanjay U. C. Sankatsing, Rieneke M. E. van Praag, Ronald Rientsma, Suzanne Jurriaans, Joep M. A. Lange, Ronald P. van Rij, Hanneke Schuitemaker, Jan M. Prins
Publikováno v:
Antiviral Therapy. 8:137-142
Starting standard antiretroviral therapy within 10 days after the onset of a primary HIV-1 infection cannot prevent the establishment of a reservoir of HIV-1-infected memory CD4 T cells. Here we studied the reservoir of HIV-1-infected memory CD4 T ce
Autor:
Jan M. Prins, Luuk Gras, Guido E.L. van den Berk, Marlous L. Grijsen, Ferdinand W. N. M. Wit, Rebecca Holman, Frank de Wolf, Andy I. M. Hoepelman
Publikováno v:
Antiviral therapy, 17(8), 1609-1613. International Medical Press Ltd
Background We assessed whether quadruple or triple-class therapy for the initial treatment of HIV-1 infection provides a virological benefit over standard triple therapy in patients with very high plasma viraemia. The assessment was made based on a n
Autor:
I. Marion de Boer-van der Kolk, Mirjam Locadia, Mirjam A. G. Sprangers, Jan M. Prins, Pythia T. Nieuwkerk
Publikováno v:
Antiviral therapy, 15(6), 913-916. International Medical Press Ltd
Background Self-report is the most commonly used measure of adherence to highly active antiretroviral therapy, but typically shows weaker associations with virological treatment outcome than more objective adherence assessment methods. Socially desir
Autor:
Mirjam, Locadia, Rosa A, van Grieken, Jan M, Prins, Henry J C, de Vries, Mirjam A G, Sprangers, Pythia T, Nieuwkerk
Publikováno v:
Antiviral therapy. 11(3)
In patients with a chronic asymptomatic HIV-1 infection and200 CD4+ T-cells/microl, the optimal timing of highly active antiretroviral therapy (HAART) initiation is unclear. It involves a trade-off between a potentially reduced risk of mortality, whe
Autor:
Sanjay U C, Sankatsing, Rieneke M E, van Praag, Ronald P, van Rij, Ronald, Rientsma, Suzanne, Jurriaans, Joep M A, Lange, Jan M, Prins, Hanneke, Schuitemaker
Publikováno v:
Antiviral therapy. 8(2)
Starting standard antiretroviral therapy within 10 days after the onset of a primary HIV-1 infection cannot prevent the establishment of a reservoir of HIV-1-infected memory CD4 T cells. Here we studied the reservoir of HIV-1-infected memory CD4 T ce
Autor:
Ronald P, van Rij, Rieneke M E, van Praag, Jan M, Prins, Ronald, Rientsma, Suzanne, Jurriaans, Joep M A, Lange, Hanneke, Schuitemaker
Publikováno v:
Antiviral therapy. 7(1)
During sustained suppression of plasma viraemia using a standard triple-drug regimen, replication-competent HIV-1 can still be recovered from resting memory CD4 T cells. In an attempt to accelerate the clearance of this pool of infected CD4 T cells,